entertainment -WSS

entertainment

author：focus 2025-10-01 12:34:29 - browse：7326

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： 'Screen and refer' systems are hurting patients

knowledge

WSS

AstraZeneca chief proposes a novel edit to the drug pricing bill

The (many) problems with a new study criticizing cancer screening

Beware reading your test results before your doctor does

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

A new House health package & hospitals’ new site

How Robert F. Kennedy Jr. distorted vaccine science

focus

entertainment

explore

Medical leaders decry Supreme Court decision on affirmative action

Covid hospitalizations on the rise, Humana says

Medicare proposal to cover medical devices draws a mixed reaction

UpToDate has a racism problem: Dr. Stanley Goldfarb

United colonoscopy coverage change 'may cost lives,' doctors say

Hubble vs. James Webb telescope images: See the difference

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Weighted lottery helped low

After affirmative action ruling, medical educators look to 'holistic review'

The 10 drugs up first for Medicare price negotiation

entertainment

Canadians with cystic fibrosis outlive Americans by a decade

House transparency, PBM reform bill gains bipartisan support

A letter from the executive editor: The 2023 STATUS List

Use doctors trained outside the U.S. to ease the physician shortage

What American doctors can learn from their Israeli counterparts

Canadians with cystic fibrosis outlive Americans by a decade

focus

knowledge

hotspot

leisure time